Tissue Engineering Market

Global Tissue Engineering Market Size (2024 to 2029)

The size of the global tissue engineering market is forecasted to showcase a CAGR of 15.67% from 2024 to 2029 and be worth USD 32.76 billion by 2029 from USD 15.82 billion in 2024.

Tissue engineering is an interdisciplinary field in which engineering and life science ideas are used to create biological substitutes that maintain or improve tissue function. Cells and biomolecules are mixed with scaffolds in this procedure. Scaffolding is a manmade or natural structure that resembles real organs. Tissue engineering is a process that involves the use of a variety of materials and cells. In addition, to replace and improve biological tissues, this technology uses physicochemical and biochemical parameters. Finally, to restore tissue surgically, the technology combines molecular and cellular methods with material engineering principles.

Global Tissue Engineering Market Drivers:

The growing demand for effective regeneration treatments as the prevalence of diabetes, obesity, and other illnesses rises due to lifestyle changes, an aging population, and an increase in the number of trauma cases are expected to drive the expansion of the global tissue engineering market. Tissue engineering treatments' potential for treating irreparable tissue damage has boosted market growth. The growth of the tissue engineering market is further is predicted to be boosted by the use of 3D bioprinters to efficiently create in vitro implants and technological developments in the field of 3D tissue engineering, such as the replacement of embryo cells with stem cells, and organ-on-a-chip technology.

Furthermore, increased government funding for medical and academic research activities boosts the tissue engineering market growth over the forecast period. Stem cell therapies have tremendous therapeutic potential in a variety of clinical settings. As a result, significant global investments in research and clinical translation have been made. Rapid advancements in stem cell research help with illness management. As the frequency of cancer, diabetes, and other chronic diseases has increased, so has research into stem cells. Researchers employ cultured stem cells to reprogram stem cells to restore an organ's normal function or construct an artificial organ transplant. Because stem cells are used in various applications, the tissue engineering market is expected to expand.

Chronic diseases, traffic accidents, and trauma injuries are all rising, fueling the development of tissue engineering treatments. In addition, the number of persons needing bone implants is increasing, owing to an increase in chronic disease cases, trauma cases, and longer average life duration. Furthermore, there is a demand for relatively inexpensive and readily available skin-replacement products, which has prompted several research groups worldwide to develop biomaterials for skin replacement. The modified tissues close wounds and stimulate dermis regeneration, which could benefit human wound healing.

Global Tissue Engineering Market Restraints:

The expansion of the global tissue engineering market is expected to be hampered by government regulations and costly treatment costs. Despite the increased interest in tissue engineering research, ethical and legislative questions have hindered progress. For example, ethical, political, and religious opposition to embryonic stem cell research, which predominantly derives from discarded non-transferred human embryos, has skewed research toward adult stem cells and severely limited federal funding in the United States.

Impact of COVID-19 on the global tissue engineering market:

Around 210 countries have been affected by COVID-19. The COVID-19 pandemic has had a significant influence on the healthcare industry. Clinical tissue engineering research has been unavailable since the COVID-19 pandemic, and non-COVID-19 clinical studies have been drastically limited. Furthermore, a considerable decrease in cell and tissue donation programs has a detrimental impact on the tissue engineering market's growth. Meanwhile, numerous pharmaceutical and biotech companies have moved their focus to developing COVID-19 therapy medications and vaccines. In viral outbreaks, tissue engineering has the potential to have a significant impact on clinical outcomes. Given their ability to apply engineering principles to biological processes, experience in collaborative situations, and predilection for technological translation from benchtop to bedside, tissue engineers could play crucial roles as leaders in the pandemic if deployed.

With the current coronavirus (COVID-19) pandemic and other viral outbreaks in the twenty-first century, new diagnostic and therapeutic ways to tackle infectious diseases are urgently needed worldwide. Tissue engineering has typically focused on applying engineering ideas to biological systems, cross-disciplinary collaboration, and quick translation of technologies from the bench to the bedside as a convergence science. However, because of the recent new coronavirus (COVID-19) pandemic, there is an obvious need for viral outbreak detection and therapies advancements.

REPORT COVERAGE:

This research report on the global tissue engineering market has been segmented and sub-segmented based on application and region.

Tissue Engineering Market - By Application:

• Cord blood & Cell Banking
• Cancer
• GI, Gynecology
• Dental
• Skin & Integumentary
• Urology
• Orthopedics, Musculoskeletal, & Spine
• Neurology
• Cardiology & Vascular
• Others

Tissue Engineering Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Due to increased awareness of stem cell therapy and an increasing geriatric population, North America accounted for the most significant share in 2023 in the global tissue engineering market. Furthermore, better technology for the detection and treatment of chronic illnesses, the availability of private and government funding, and high healthcare spending contribute to tissue engineering gaining a more significant proportion of the regional market. Due to the availability of government money and substantial private-sector investments, the United States is expected to account for a substantial revenue share. Regarding technological innovation and translational advancement, the transformative impact of employing regenerative medicine clinically is essential.

Due to the rising demand for regenerative medicines, the Asia Pacific geographical sector is predicted to develop quickly over the forecast period. Medical tourism is also on the rise, helping propel the sector forward. Furthermore, the rising burden and changing lifestyle are expected to impact market growth over the forecast period substantially. For example, smoking causes more than one in every five cardiovascular diseases in Asia, such as heart attack and stroke. Japan is one of the most forward-thinking countries regarding tissue engineering technology. Furthermore, an increase in the frequency of clinical disorders, such as cancer in Asia, is likely to fuel expanding the tissue engineering market in the area. Its regulatory approach also encourages the approval of clinical trials more quickly.

Due to growing research efforts, rising demand for organ transplants, an increasing number of market players endeavors to extend their presence in the region, and more robust adoption of stem cell research in numerous European countries, Europe is predicted to grow at a considerable CAGR. Furthermore, because of expanding government support, rising demand for cosmetic procedures, and favorable rules and data requirements in European healthcare systems, France and the United Kingdom provide considerable growth potential for companies in the tissue engineering market.

KEY MARKET PARTICIPANTS:

Stryker, Allergan, Medtronic, Zimmer, Baxter International, Integra LifeSciences, Organovo Holdings Inc., Cook Medical, DePuy Synthes, and Acelity are some of the prominent companies operating in the global tissue engineering market and profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

• ACell and MyungMoon Bio Co. Ltd. announced an exclusive distribution agreement for ACell's wound treatment treatments Cytal Wound Matrix and MicroMatrix in South Korea in March 2019.
• ACell received an additional 510(k) FDA clearance for their Gentrix product line in April 2019. As a result, the indications for using the company's Gentrix surgical matrix products have grown.
• The COVID-19 pandemic has caused a significant interruption in ordinary scientific tasks such as tissue engineering and regenerative therapies, according to Medscape in July 2020.
• In November 2020, Stryker stated that it had cleared all regulatory hurdles in the path of its planned USD 4.7 billion acquisition of Wright Medical. The contract proposal was started in November 2019 and will be completed in November 2020.
• Medtronic plc bought Companion Medical, Inc. in August 2020. The addition of Companion Medical's InPen to the Medtronic portfolio expands the company's ability to serve diabetic patients and provide them with a unique and comprehensive service environment regardless of how insulin is delivered.